chlorpromazine   Click here for help

GtoPdb Ligand ID: 83

Synonyms: chlorpromazine HCl | Largactil® | Thorazine®
Approved drug PDB Ligand
chlorpromazine is an approved drug (FDA (1957))
Compound class: Synthetic organic
Comment: Chlorpromazine was the first antipsychotic drug to be discovered. It is one of the most sedating of the typical antipsychotics and also causes antimuscarinic effects.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: chlorpromazine

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 31.78
Molecular weight 318.1
XLogP 4.92
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C
Isomeric SMILES CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C
InChI InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
InChI Key ZPEIMTDSQAKGNT-UHFFFAOYSA-N
Bioactivity Comments
Chlorpromazine is one of a number of drugs that are cationic amphiphilic in nature, for which anti-SARS-CoV-2 activity has been identified in drug repurposing screens. Tummino et al. (2021; bioRxiv preprint PMID: 33791693 target="_blank") suggest that this antiviral activity is most likely a result of the drug promoting phospholipidosis via disruption of lipid homeostasis.
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
5-HT2A receptor Rn Antagonist Inverse agonist 8.7 pKi - 3
pKi 8.7 [3]
5-HT6 receptor Rn Antagonist Inverse agonist 8.4 pKi - 13
pKi 8.4 [13]
H1 receptor Hs Antagonist Antagonist 8.2 pKi - 7
pKi 8.2 [7]
5-HT2A receptor Primary target of this compound Hs Antagonist Inverse agonist 8.1 pKi - 7
pKi 8.1 [7]
5-HT2C receptor Hs Antagonist Antagonist 7.6 – 8.2 pKi - 5,7
pKi 7.6 – 8.2 [5,7]
D4 receptor Hs Antagonist Antagonist 7.8 pKi - 8
pKi 7.8 [8]
5-HT6 receptor Hs Antagonist Inverse agonist 7.7 – 7.8 pKi - 6,12
pKi 7.7 – 7.8 [6,12]
5-HT7 receptor Hs Antagonist Inverse agonist 7.6 pKi - 12
pKi 7.6 [12]
5-HT7 receptor Rn Antagonist Inverse agonist 7.6 pKi - 13
pKi 7.6 [13]
D2 receptor Rn Antagonist Antagonist 7.5 pKi - 15
pKi 7.5 [15]
α2B-adrenoceptor Hs Antagonist Antagonist 6.6 – 8.3 pKi - 1-2,11
pKi 6.6 – 8.3 [1-2,11]
D3 receptor Hs Antagonist Antagonist 7.2 – 7.5 pKi - 4,14
pKi 7.2 – 7.5 [4,14]
D2 receptor Hs Antagonist Antagonist 7.0 – 7.6 pKi - 4,14
pKi 7.0 – 7.6 [4,14]
D3 receptor Rn Antagonist Antagonist 7.2 pKi - 15
pKi 7.2 [15]
D1 receptor Hs Antagonist Antagonist 7.1 pKi - 16
pKi 7.1 [16]
D5 receptor Hs Antagonist Antagonist 6.9 pKi - 16
pKi 6.9 [16]
α2C-adrenoceptor Hs Antagonist Antagonist 5.9 – 7.4 pKi - 1-2,11
pKi 5.9 – 7.4 [1-2,11]
5-HT1A receptor Hs Antagonist Antagonist 6.2 pKi - 9
pKi 6.2 [9]
α2A-adrenoceptor Hs Antagonist Antagonist 5.5 – 6.6 pKi - 1-2,11
pKi 5.5 – 6.6 [1-2,11]
5-HT7 receptor Mm Antagonist Inverse agonist 5.3 pKi - 10
pKi 5.3 [10]
Selectivity at ion channels
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
TRPC5 Hs Channel blocker - - - -
Maxi Cl- Hs Activator (extracellular chlorpromazine) - - - -